AZNAstraZenecaRunning, no new patients
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Advanced Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 111 (final count)
- Started
- Jun 27, 2023
- Main results expected
- Mar 30, 2026
- Fully finished
- Dec 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs)
Measured over: From the date of first dose of IMP until 6 months after the initiation of study intervention
Objective response rate (ORR)
Measured over: From the first dose of IMP until progression, or the last evaluable assessment in the absence of progression [approx. up to 33 months]
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05883644 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC